PLSE vs UNH: fair value comparison
Pulse Biosciences, Inc. and UnitedHealth Group Incorporated · Updated 2026-10-19
PLSE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PLSE currently ranks higher by quality score.
| PLSE | UNH | |
|---|---|---|
| Verdict | No estimate yet | Undervalued |
| Last price | $44.43 | $379.30 |
| 12-month range | $12.66–$55.20 | $259.02–$436.35 |
| Rank by discount to fair value | — | #34 of 108 Healthcare |
| Rank by quality score | #207 of 301 Healthcare | #208 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Moderate |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: PLSE fair value analysis · UNH fair value analysis